Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

There is a study investigating cabozantinib plus nivolumab and cabozantinib plus nivolumab plus ipilimumab (Yervoy) in patients with urothelial carcinoma and other genitourinary malignancies, states Apolo. Sixty-six patients have been enrolled with data being presented on 46 patients with a median follow-up of 12.4 months.

The overall response rate (ORR) for the entire cohort is 34%, with the bladder cancer cohort seeing an ORR of 44%. The median overall survival has not yet been met and the progression-free survival is 6.4 months, explains Apolo.